Cellectar Biosciences, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) therapeutic, CLR 131, is in a Phase 1 clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a Phase 2 clinical study in R/R MM and a range of B-cell malignancies. The company's product pipeline also includes two preclinical PDC chemotherapeutic programs, which include CLR 1700 that is designed to treat a broad range of hematologic cancers; and CLR 1900, which is targeted to treat select solid tumors. It also has collaborative PDC programs with Pierre Fabre to develop CLR 1800 Series; with Avicenna Oncology GMBH to develop CLR 2000 Series; and Onconova Therapeutics, Inc. to develop CLR 2100 and 2200 Series. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120
Debt
Debt-to-Equity RatioN/A
Current Ratio3.64
Quick Ratio3.64
Price-To-Earnings
Trailing P/E Ratio-0.63
Forward P/E Ratio-0.92
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$6.17 per share
Price / Book1.08
Profitability
EPS (Most Recent Fiscal Year)($10.70)
Net Income$-13,560,000.00
Net MarginsN/A
Return on Equity-178.37%
Return on Assets-139.16%
Miscellaneous
Employees15
Outstanding Shares1,770,000
Market Cap$11.85
Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions
What is Cellectar Biosciences' stock symbol?
Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."
When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?
Shares of Cellectar Biosciences reverse split before market open on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.
How were Cellectar Biosciences' earnings last quarter?
Cellectar Biosciences Inc (NASDAQ:CLRB) issued its earnings results on Friday, May, 11th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.00) by $0.10. View Cellectar Biosciences' Earnings History.
When is Cellectar Biosciences' next earnings date?
What is the consensus analysts' recommendation for Cellectar Biosciences?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Cellectar Biosciences' key competitors?
Some companies that are related to Cellectar Biosciences include vTv Therapeutics (VTVT), Moleculin Biotech (MBRX), Heat Biologics (HTBX), Evoke Pharma (EVOK), Acerus Pharmaceuticals (TRLPF), AzurRx BioPharma (AZRX), Avenue Therapeutics (ATXI), Chiasma (CHMA), Capricor Therapeutics (CAPR), Onconova Therapeutics (ONTX), Nemus Bioscience (NMUS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), PLx Pharma (PLXP) and KITOV PHARMA LT/S (KTOV).
Who are Cellectar Biosciences' key executives?
Cellectar Biosciences' management team includes the folowing people:
- Mr. James V. Caruso, CEO, Pres & Director (Age 59)
- Mr. Jarrod Longcor, Chief Bus. Officer (Age 45)
- Dr. John E Friend II, M.D., VP & Chief Medical Officer (Age 48)
- Mr. Brian M. Posner, VP & CFO (Age 56)
- Gregory J. Lynch, Sec.
Has Cellectar Biosciences been receiving favorable news coverage?
Media coverage about CLRB stock has been trending positive recently, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a media sentiment score of 0.35 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 45.33 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Cellectar Biosciences?
Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cellectar Biosciences' stock price today?
One share of CLRB stock can currently be purchased for approximately $6.69.
How big of a company is Cellectar Biosciences?
Cellectar Biosciences has a market capitalization of $11.85 million. The biopharmaceutical company earns $-13,560,000.00 in net income (profit) each year or ($10.70) on an earnings per share basis. Cellectar Biosciences employs 15 workers across the globe.
How can I contact Cellectar Biosciences?
Cellectar Biosciences' mailing address is 3301 AGRICULTURE DRIVE, MADISON WI, 53716. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]
MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
